NOVARTIS logo.jpg
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
September 19, 2021 07:30 ET | Novartis Pharma AG
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced...
NOVARTIS logo.jpg
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
September 17, 2021 07:30 ET | Novartis Pharma AG
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks,...
NOVARTIS logo.jpg
Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021
September 16, 2021 18:05 ET | Novartis Pharma AG
New quality of life data for 177Lu-PSMA-617 plus standard of care shows delay in worsening of health-related quality of life (HRQoL) and pain in heavily pre-treated patients with PSMA-positive...
Sandoz logo
Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine
September 08, 2021 07:30 ET | Novartis Pharma AG
Sandoz enters into commercialization agreement for biosimilar bevacizumab with Bio-Thera Solutions, Ltd., for treatment of multiple types of cancers1,2Sandoz is committed to building on its leading...
NOVARTIS logo.jpg
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran)
August 31, 2021 19:01 ET | Novartis Pharma AG
Agreement follows positive NICE recommendation and commits to deliver Leqvio® (inclisiran) access via a population health management approach identifying eligible patients across England1 Over three...
NOVARTIS logo.jpg
Novartis presents important overall survival and quality-of-life results across solid tumor portfolio, among other key data at ESMO
August 30, 2021 01:15 ET | Novartis Pharma AG
New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line settingHealth-related quality of life, pain and safety...
NOVARTIS logo.jpg
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
August 24, 2021 01:15 ET | Novartis Pharma AG
Phase III BELINDA study did not meet primary endpoint of event-free survival for patients with aggressive B-cell non-Hodgkin lymphoma who had primary refractory disease or who relapsed within 12...
NOVARTIS logo.jpg
Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA
August 03, 2021 01:15 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will...
NOVARTIS logo.jpg
Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged.
July 21, 2021 01:00 ET | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Net sales in Q2 grew +9% (cc¹, +14% USD): Pharmaceuticals BU grew +12% (cc, +18% USD) with continued strong growth from Entresto (+46% cc), Cosentyx (+21%...
NOVARTIS logo.jpg
Novartis: forte performance au deuxième trimestre, soutenue par la dynamique des marques clés de croissance; prévisions pour l’exercice 2021 inchangées
July 21, 2021 01:00 ET | Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T2 en progression de +9% (tcc1, +14% USD): Pharmaceuticals: cette unité d’affaires (UO) a vu son chiffre d’affaires progresser de...